Roivant Sciences Ltd. Q3 FY2024 earnings call

• Pipeline is one of the most exciting in late-stage biotech, anchored by FCRN and brepasitinib. • 2025 is a significant year with milestones like validating API CRM franchise with MG and CIDP data, registrational readout in dermatomyositis for brepasitinib, and a new indication for brepasitinib in cutaneous sarcoidosis. • Clinical execution is a focus, with six INDs cleared at Abutavant, trials beginning, and ongoing work at Immunavand. • Financials: Cash balance of $5.2 billion as of December 31, 2024; R&D expense of $142 million (adjusted $131 million); G&A of $142 million (adjusted $71 million); no debt on balance sheet. • Cutaneous sarcoidosis proof of concept study for brepasitinib, with proof of concept data from an investigator-initiated trial showing promising results.

No detailed financial performance data for product segments in terms of absolute revenue and contribution percentages provided in the transcript.

• 2025 has important milestones including MG and CIDP data, dermatomyositis registrational readout, trial start for brepasitinib in cutaneous sarcoidosis, and LNP litigation jury trial in September. • Expectations for data from MG and CIDP trials, brepasitinib dermatomyositis study, and cutaneous sarcoidosis proof of concept study. • Forward-looking to adding to pipeline and continuing clinical work.

• LNP litigation with Moderna and Pfizer BioNTech, including summary judgment phase and jury trial in September, with potential outcomes affecting the company.

Q: Review bateclimab efficacy bars and additional GD data.

A: Matt Gline discussed deeper IgG suppression being better, looking for dose response in MG study, and six-month remission data in Graves' disease.

Q: LNP litigation and summary judgment.

A: Discussed fourteen ninety-eight and the government's role in the patent infringement liability.

Q: Cutaneous sarcoidosis trial design and Graves' remission data.

A: Proof of concept study for cutaneous sarcoidosis, looking for response rates and remission data in Graves' disease.

Q: ImmunoVAN data and commitment to MG/CIDP.

A: Commitment to advancing fourteen o two into MG and CIDP regardless of data, and powering of cutaneous sarcoidosis trial.

Q: Investment in ImmunoGen and data focus.

A: Investment in ImmunoGen due to attractive opportunity and Graves' potential, and focus on form factor and dosing in data.

Q: BREPO Phase three and competitive landscape.

A: Excitement for brepasitinib's Phase three readout in dermatomyositis, and competitive dynamics.

Q: Pace of additional brepasitinib indications.

A: Actively evaluating additional indications, unveiling as ready, with many potential opportunities.